DK3618875T3 - Kombinationsterapi omfattende en raf-inhibitor og trametinib - Google Patents

Kombinationsterapi omfattende en raf-inhibitor og trametinib Download PDF

Info

Publication number: DK3618875T3
Authority: DK; Denmark
Prior art keywords: trametinib; combination therapy; raf inhibitor; therapy including; raf
Prior art date: 2017-05-02

Application number

DK18726224.1T

Other languages

English (en)

Inventor

Vesselina Cooke

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-05-02

Filing date

2018-04-30

Publication date

2023-07-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62218018&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3618875(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-04-30 Application filed by Novartis Ag filed Critical Novartis Ag

2023-07-10 Application granted granted Critical

2023-07-10 Publication of DK3618875T3 publication Critical patent/DK3618875T3/da

Links

238000002648 combination therapy Methods 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 title 1
229960004066 trametinib Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyridine Compounds (AREA)
Iron Core Of Rotating Electric Machines (AREA)

DK18726224.1T 2017-05-02 2018-04-30 Kombinationsterapi omfattende en raf-inhibitor og trametinib DK3618875T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201762500108P	2017-05-02	2017-05-02
US201862656423P	2018-04-12	2018-04-12
PCT/IB2018/052989 WO2018203219A1 (en)	2017-05-02	2018-04-30	Combination therapy

Publications (1)

Publication Number	Publication Date
DK3618875T3 true DK3618875T3 (da)	2023-07-10

Family

ID=62218018

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK18726224.1T DK3618875T3 (da)	2017-05-02	2018-04-30	Kombinationsterapi omfattende en raf-inhibitor og trametinib

Country Status (18)

Country	Link
US (2)	US11266653B2 (da)
EP (2)	EP3618875B1 (da)
JP (2)	JP7309614B2 (da)
KR (2)	KR20240032157A (da)
CN (1)	CN110494166B (da)
AU (1)	AU2018262891B2 (da)
BR (1)	BR112019022511A2 (da)
CA (1)	CA3057969A1 (da)
CL (1)	CL2019003091A1 (da)
DK (1)	DK3618875T3 (da)
ES (1)	ES2952265T3 (da)
FI (1)	FI3618875T3 (da)
IL (2)	IL311471A (da)
MX (1)	MX2019012884A (da)
PL (1)	PL3618875T3 (da)
PT (1)	PT3618875T (da)
TW (1)	TWI798218B (da)
WO (1)	WO2018203219A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2017329090B9 (en)	2016-09-19	2019-09-05	Novartis Ag	Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
CN111201023A (zh) *	2017-08-11	2020-05-26	启码策有限公司	用于靶向癌症中的多个突变的药物组合物
JP2022514056A (ja) *	2018-12-20	2022-02-09	ノバルティスアーゲー	癌の治療に使用するためのＲａｆ阻害剤及びＣＤＫ４／６阻害剤による組み合わせ療法
TW202140029A (zh) *	2020-02-18	2021-11-01	瑞士商諾華公司	用於治療ｂｒａｆ突變型ｎｓｃｌｃ的包含ｒａｆ抑制劑之治療組合
KR20220032607A (ko) *	2020-02-27	2022-03-15	국립대학법인 홋가이도 다이가쿠	항암제를 스크리닝하는 방법 및 췌장암 치료를 위한 키나아제 억제제의 조합 의약
CN113440616A (zh) *	2020-03-25	2021-09-28	上海科州药物研发有限公司	Ras或raf突变型癌症的联合疗法
WO2021229439A1 (en) *	2020-05-12	2021-11-18	Novartis Ag	Therapeutic combinations comprising a craf inhibitor
TW202227088A (zh) *	2020-08-31	2022-07-16	瑞士商諾華公司	組合療法
WO2023145530A1 (ja) *	2022-01-27	2023-08-03	国立大学法人東北大学	癌治療剤
TW202342766A (zh)	2022-03-02	2023-11-01	瑞士商諾華公司	用於癌症治療之精準療法
US11957759B1 (en)	2022-09-07	2024-04-16	Arvinas Operations, Inc.	Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
CN117919235A (zh) *	2022-10-25	2024-04-26	上海润石医药科技有限公司	一种萘酰胺化合物治疗kras突变相关疾病的用途
WO2024088275A1 (zh) *	2022-10-25	2024-05-02	中国科学院上海药物研究所	一种萘酰胺化合物治疗耐药性肿瘤的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1219753C (zh)	2000-07-19	2005-09-21	沃尼尔·朗伯公司	4－碘苯氨基苯氧肟酸的氧合酯
CN101006086B (zh)	2004-06-11	2010-09-29	日本烟草产业株式会社	用于治疗癌症的5-氨基-2,4,7-三氧代-3,4,7,8-四氢-2H-吡啶并[2,3-d]嘧啶衍生物和相关化合物
TWI505828B (zh)	2010-12-20	2015-11-01	葛蘭素史克智慧財產（第二）有限公司	新穎醫藥組成物
AR091876A1 (es) *	2012-07-26	2015-03-04	Novartis Ag	Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
AU2013313050A1 (en)	2012-09-04	2015-03-26	Novartis Ag	Method of adjuvant cancer treatment
US9242969B2 (en)	2013-03-14	2016-01-26	Novartis Ag	Biaryl amide compounds as kinase inhibitors
AU2017329090B9 (en) *	2016-09-19	2019-09-05	Novartis Ag	Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor

2018
- 2018-04-30 DK DK18726224.1T patent/DK3618875T3/da active
- 2018-04-30 CA CA3057969A patent/CA3057969A1/en active Pending
- 2018-04-30 TW TW107114676A patent/TWI798218B/zh active
- 2018-04-30 FI FIEP18726224.1T patent/FI3618875T3/fi active
- 2018-04-30 EP EP18726224.1A patent/EP3618875B1/en active Active
- 2018-04-30 EP EP23166366.7A patent/EP4272740A1/en active Pending
- 2018-04-30 PL PL18726224.1T patent/PL3618875T3/pl unknown
- 2018-04-30 ES ES18726224T patent/ES2952265T3/es active Active
- 2018-04-30 BR BR112019022511-0A patent/BR112019022511A2/pt unknown
- 2018-04-30 JP JP2019558725A patent/JP7309614B2/ja active Active
- 2018-04-30 KR KR1020247006274A patent/KR20240032157A/ko active Search and Examination
- 2018-04-30 IL IL311471A patent/IL311471A/en unknown
- 2018-04-30 US US16/610,482 patent/US11266653B2/en active Active
- 2018-04-30 AU AU2018262891A patent/AU2018262891B2/en active Active
- 2018-04-30 CN CN201880023601.0A patent/CN110494166B/zh active Active
- 2018-04-30 IL IL270224A patent/IL270224B1/en unknown
- 2018-04-30 MX MX2019012884A patent/MX2019012884A/es unknown
- 2018-04-30 WO PCT/IB2018/052989 patent/WO2018203219A1/en unknown
- 2018-04-30 PT PT187262241T patent/PT3618875T/pt unknown
- 2018-04-30 KR KR1020197031788A patent/KR102641827B1/ko active IP Right Grant
2019
- 2019-10-28 CL CL2019003091A patent/CL2019003091A1/es unknown
2022
- 2022-01-26 US US17/584,901 patent/US20220143036A1/en active Pending
2023
- 2023-07-05 JP JP2023110949A patent/JP2023145467A/ja active Pending

Also Published As

Publication number	Publication date
MX2019012884A (es)	2020-01-14
IL270224A (da)	2019-12-31
JP2020518568A (ja)	2020-06-25
WO2018203219A1 (en)	2018-11-08
US20200246346A1 (en)	2020-08-06
CN110494166A (zh)	2019-11-22
KR20190141164A (ko)	2019-12-23
RU2019134757A (ru)	2021-06-02
EP4272740A1 (en)	2023-11-08
TWI798218B (zh)	2023-04-11
BR112019022511A2 (pt)	2020-05-12
JP7309614B2 (ja)	2023-07-18
KR102641827B1 (ko)	2024-03-04
PL3618875T3 (pl)	2023-10-23
PT3618875T (pt)	2023-08-07
AU2018262891B2 (en)	2021-04-01
AU2018262891A1 (en)	2019-10-17
IL270224B1 (en)	2024-04-01
EP3618875A1 (en)	2020-03-11
EP3618875B1 (en)	2023-04-05
CN110494166B (zh)	2022-11-08
US11266653B2 (en)	2022-03-08
US20220143036A1 (en)	2022-05-12
CA3057969A1 (en)	2018-11-08
CL2019003091A1 (es)	2020-02-07
JP2023145467A (ja)	2023-10-11
RU2019134757A3 (da)	2021-08-17
FI3618875T3 (fi)	2023-07-04
ES2952265T3 (es)	2023-10-30
KR20240032157A (ko)	2024-03-08
TW201842914A (zh)	2018-12-16
IL311471A (en)	2024-05-01

Publication	Publication Date	Title
DK3618875T3 (da)	2023-07-10	Kombinationsterapi omfattende en raf-inhibitor og trametinib
DK3595397T3 (da)	2022-01-03	Listen-before-talk-procedure i en trådløs indretning og trådløs indretning
DK3448386T3 (da)	2021-04-26	Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
DK3610005T3 (da)	2021-12-13	Peptidligase og anvendelse deraf
DK3307707T3 (da)	2020-12-21	Halogensubstituerede phenoxyphenylamidiner og anvendelsen deraf som fungicider
DK3389658T3 (da)	2021-01-11	Glycosidasehæmmere og anvendelser deraf
DK3283106T3 (da)	2022-01-10	Terapeutiske antistoffer og anvendelser deraf
DK3285705T3 (da)	2020-11-02	Sårpude og et selvklæbende element omfattende en sårpude
DK3270915T3 (da)	2020-06-15	Kombineret behandling med en TLR7-agonist og en HBV-kapsidsamlingsinhibitor
DK3210977T3 (da)	2019-07-01	Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf
DK3452463T3 (da)	2021-04-26	Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK2990084T3 (da)	2020-02-17	Gangtræningsapparat og styringsfremgangsmåde dertil
IL264931B (en)	2021-09-30	Medicinal combinations containing a raf inhibitor and an erk inhibitor
DK3532459T3 (da)	2023-10-30	Lsd1-hæmmere og medicinske anvendelser deraf
DK3256598T3 (da)	2021-01-11	Svampestammer og anvendelsesfremgangsmåder
DK3621694T3 (da)	2023-09-11	Lrrc33-inhibitorer og anvendelse heraf
DK3747472T3 (da)	2024-06-10	Terapeutiske kombinationer af en cd19-hæmmer og en btk-hæmmer
DK3265641T3 (da)	2020-03-16	Stigørenhed og fremgangsmåde
DK3268374T3 (da)	2020-01-02	Kv1.3-inhibitorer og deres medicinske anvendelse
DK3612579T3 (da)	2022-02-14	Pultrudat, fremstilling og anvendelse heraf
DK3325618T3 (da)	2020-08-10	Hidtil ukendte trypsin-isoformer og anvendelse deraf
DK3516160T3 (da)	2024-04-15	Brøndanordning og tilhørende fremgangsmåder
DK3426243T3 (da)	2021-07-19	3-phosphoglyceratdehydrogenase-inhibitorer og anvendelser deraf
DK3679220T3 (da)	2021-11-01	Brøndredskabsforankring og tilhørende fremgangsmåder
DK3947375T3 (da)	2024-05-21	Imidazolonylquinolinforbindelser og terapeutiske anvendelser deraf